Pulmonology

Staying Current in Pulmonology: COPD, Asthma, ILD, and Lung Cancer Research

Pulmonology spans some of the most rapidly evolving areas in internal medicine. Biological therapies have transformed severe asthma management. Antifibrotic drugs changed the prognosis of idiopathic pulmonary fibrosis. Lung cancer immunotherapy has produced durable responses unimaginable a decade ago. This guide covers practical strategies for pulmonologists to stay current across the full scope of the specialty.

Core journals for pulmonologists

American Journal of Respiratory and Critical Care Medicine (AJRCCM) — the highest-impact pulmonology journal, covers full scope of the specialty
Chest — ACCP flagship, particularly strong on clinical practice and guidelines
Thorax — European respiratory journal with strong clinical evidence
European Respiratory Journal (ERJ) — ERS flagship, essential for international evidence
Lancet Respiratory Medicine — high-impact clinical trials and reviews

COPD: ongoing management evolution

The GOLD (Global Initiative for Chronic Obstructive Lung Disease) strategy document is updated annually and represents the most clinically actionable COPD reference. Key areas where COPD evidence continues to evolve:

LAMA/LABA/ICS combinations — positioning of triple therapy based on exacerbation history and eosinophil counts (IMPACT, ETHOS, KRONOS trials)
Type 2 inflammation biomarkers — blood eosinophils as a predictive biomarker for ICS response
Dupilumab in COPD — the BOREAS and NOTUS trials extending biologics into COPD with type 2 inflammation
Lung volume reduction — bronchoscopic approaches and evolving patient selection criteria

Severe asthma biologics: the fastest-moving therapeutic area

The landscape of biologic therapy for severe asthma has expanded dramatically since omalizumab's 2003 approval. Current approved biologics targeting different pathways:

Anti-IgE: Omalizumab (Xolair) — for allergic asthma
Anti-IL-5/IL-5R: Mepolizumab, reslizumab, benralizumab — for eosinophilic asthma
Anti-IL-4/IL-13 (IL-4Rα): Dupilumab — for type 2 inflammatory asthma
Anti-TSLP: Tezepelumab (Tezspire) — broadest indication, includes non-eosinophilic disease

Comparative effectiveness data, real-world outcomes, and guidance on biologic selection and switching continue to evolve. The GINA (Global Initiative for Asthma) guidelines, updated annually, provide the most current framework for biologic selection.

Key emerging question: Which patients with severe asthma benefit from which biologic, and what biomarkers predict response? The GINA severe asthma section and emerging precision medicine data are the most important reading in this area.

Interstitial lung disease: the antifibrotic era

Idiopathic pulmonary fibrosis (IPF) was uniformly fatal within 3 to 5 years before pirfenidone and nintedanib demonstrated meaningful disease-slowing in CAPACITY/ASCEND and INPULSIS trials respectively. Current ILD literature priorities:

Progressive pulmonary fibrosis — the broader category beyond IPF, including connective tissue disease-ILD and fibrotic hypersensitivity pneumonitis
Nintedanib in progressive fibrosis beyond IPF (SENSCIS, INBUILD trial data)
Antifibrotic combinations — emerging trial data
The role of bronchoscopic cryobiopsy in ILD diagnosis
Lung transplant outcomes data and prognostic scoring

Sleep medicine: overlap with pulmonology practice

Obstructive sleep apnea management has expanded with the approval of tirzepatide data showing significant AHI reduction (SURMOUNT-OSA trial) and the FDA approval of carbonic anhydrase inhibitor therapy for central sleep apnea subtypes. Pulmonologists with sleep practices should monitor:

CPAP adherence and alternatives — hypoglossal nerve stimulation (STAR trial follow-up data)
OSA and cardiovascular outcomes — SAVE, ISAACC trials and their interpretation
Obesity pharmacotherapy effects on OSA severity

Lung cancer and the pulmonologist's role

Pulmonologists are often the first to evaluate lung nodules and establish diagnoses. Key areas of lung cancer literature relevant to pulmonary practice:

Lung cancer screening — updated USPSTF criteria (2021), implementation and follow-up protocols
Bronchoscopic diagnostic techniques — robotic bronchoscopy, electromagnetic navigational bronchoscopy yield data
Liquid biopsy — circulating tumor DNA in diagnosis and monitoring
Early-stage NSCLC — adjuvant immunotherapy trials (IMpower010, KEYNOTE-091)

Conference priorities in pulmonology

ATS International Conference (May) — primary venue for US pulmonology research
ERS International Congress (September) — European respiratory, essential for COPD and asthma evidence
CHEST Annual Meeting (October) — ACCP conference, strong on clinical practice and critical care overlap

Get the most important papers in your specialty every week

MDInformed curates the five most clinically relevant papers from 35 million publications and delivers them as a structured digest — free forever.

Join the waitlist →